Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion

Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion

SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Aspire, the Singapore-headquartered fintech, today announced a series of regulatory milestones marking a major step in its global expansion. Over the past year alone, the company has secured eight licenses...

DIFC becomes top five global hub for hedge fund managers - over 100 hedge funds now registered in the Centre

DIFC becomes top five global hub for hedge fund managers - over 100 hedge funds now registered in the Centre

DUBAI, UAE, Dec. 15, 2025 /PRNewswire/ -- DIFC, the leading global financial centre in the Middle East, Africa and South Asia region, has registered its 100th hedge fund, reflecting its dominance in the sector and successful journey to becoming a...

JinkoSolar Supplied Modules to Trinity Energy for Costco Warehouse in Washington State

JinkoSolar Supplied Modules to Trinity Energy for Costco Warehouse in Washington State

CAMPBELL, Calif., Oct. 27, 2025 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. (the "Company," or "JinkoSolar") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that the company has supplied...

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[ 1] SINGAPORE, May 30, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised...

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis...

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain...

menu
menu